LEXX
Lexaria Bioscience Corp.
NASDAQ · Healthcare · Biotechnology · CA
$14.15
+14.85%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
Market Cap
$23.38M
MomentumView details →
1D Return
+14.85%
YTD Return
+36.76%
RSI (14)
63.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
Market Cap
$23.38M
RSI (14)
63.5
MomentumView details →
1D Return
+14.85%
YTD Return
+36.76%
SummaryUpdated May 1, 2026
Lexaria Bioscience Corp. (NASDAQ:LEXX) is a Canadian biotechnology company founded in 2004 and headquartered in Kelowna, British Columbia. The company went public on NASDAQ in January 2021. Lexaria operates as a drug delivery technology company focused on developing and commercializing its proprietary DehydraTECH platform, which enhances the oral absorption of active pharmaceutical ingredients. The company maintains an in-house research laboratory and holds an intellectual property portfolio comprising 23 granted patents and approximately 50 pending patents worldwide.
Similar companies
Latest newsMore news →
Lexaria Bioscience Corp. received a cash rebate of AUD$3,666,611.98 (USD$2.6 million) from the Australian Tax Office, deposited into the account of its wholly-owned subsidiary Lexaria (AU) Pty Ltd.4d agoLexaria Bioscience announced completion of pharmacokinetic bioanalysis testing in its 2026 Animal Study #2, which evaluated oral delivery of amycretin and retatrutide using its DehydraTECH platform, showing significant absorption improvements.12d agoLexaria Bioscience Corp. entered into a Material Transfer Agreement with PegBio Co., Ltd to investigate Lexaria's DehydraTECH technology with a PegBio molecule under development for the GLP-1 industry.23d ago